Literature DB >> 22902762

Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures.

Sunil Samuel1, David H Bruining, Edward V Loftus, Kelvin T Thia, Kenneth W Schroeder, William J Tremaine, William A Faubion, Sunanda V Kane, Darrell S Pardi, Piet C de Groen, William S Harmsen, Alan R Zinsmeister, William J Sandborn.   

Abstract

BACKGROUND & AIMS: Endoscopic healing is likely to become an important goal for treatment of patients with ulcerative colitis (UC). A simple validated endoscopic index is needed. We validated the previously developed UC Colonoscopic Index of Severity (UCCIS).
METHODS: In a prospective study, 50 patients with UC were examined by colonoscopy; we analyzed videos of rectum and sigmoid, descending, transverse, and cecum/ascending colon. Eight gastroenterologists blindly rated 4 mucosal lesions (for vascular pattern, granularity, friability, ulceration) and severity of damage to each segment and overall. The global assessment of endoscopic severity (GAES) was based on a 4-point scale and 10-cm visual analogue scale. Correlation of the UCCIS score with clinical indexes (clinical activity index and simple clinical colitis activity index), patient-defined remission, and laboratory measures of disease activity (levels of C-reactive protein, albumin, and hemoglobin and platelet counts) were estimated by using the Pearson (r) or Spearman (r(s)) method.
RESULTS: Interobserver agreement was good to excellent for the 4 mucosal lesions evaluated by endoscopy and the GAES. The UCCIS calculated for our data accounted for 74% (R(2) = 0.74) and 80% (R(2) = 0.80) of the variation in the GAES and visual analogue scores, respectively (P < .0001). The UCCIS also correlated with clinical activity index (r = 0.52, P < .001), simple clinical colitis activity index (r = 0.62, P < .0001), and patient-defined remission (r = 0.43, P < .01). The UCCIS also correlated with levels of C-reactive protein (r(s) = 0.56, P < .001), albumin (r = -0.55, P < .001), and hemoglobin (r = -0.39, P < .01). A rederivation of the equation for the UCCIS by using the data from a previous study combined with those of the current study (n = 101) yielded similar results.
CONCLUSIONS: The UCCIS is a simple tool that provides reproducible results in endoscopic scoring of patients with UC.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22902762     DOI: 10.1016/j.cgh.2012.08.003

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  32 in total

Review 1.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

2.  Ulcerative colitis: UCCIS--a reproducible tool to assess mucosal healing.

Authors:  Helmut Neumann; Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-16       Impact factor: 46.802

Review 3.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis?

Authors:  Byong Duk Ye
Journal:  Dig Dis Sci       Date:  2014-01-17       Impact factor: 3.199

5.  Assessing disease activity in patients with ulcerative colitis.

Authors:  Alissa Walsh; Simon Travis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

Review 6.  "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

Authors:  Cristiano Pagnini; Francesca Menasci; Stefano Festa; Gianenrico Rizzatti; Gianfranco Delle Fave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

7.  Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.

Authors:  Marcello Cintolo; Giuseppe Costantino; Socrate Pallio; Walter Fries
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 8.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

Review 9.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

10.  Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity.

Authors:  F Maione; M C Giglio; G Luglio; A Rispo; M D'Armiento; B Manzo; G Cassese; P Schettino; N Gennarelli; S Siciliano; F P D'Armiento; G D De Palma
Journal:  Tech Coloproctol       Date:  2017-07-03       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.